-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis expects interim Phase 2 BALLI-01 data for lasme-cel in Q4 2026

PUBT·05/11/2026 20:37:47
Listen to the news
Cellectis expects interim Phase 2 BALLI-01 data for lasme-cel in Q4 2026
  • Cellectis outlined 2026 clinical catalysts for its allogeneic CAR-T portfolio, with interim pivotal Phase 2 data for lasme-cel in relapsed or refractory B-cell acute lymphoblastic leukemia slated for Q4 2026.
  • Earlier Phase 1 findings have already been presented, indicating broad responses that supported progression into pivotal testing, with a safety profile viewed as manageable.
  • Full Phase 1 results for eti-cel in relapsed or refractory non-Hodgkin lymphoma are scheduled for release in Q4 2026, extending initial readouts that signaled anti-tumor activity in heavily pretreated patients.
  • Regulatory timeline targets Biologics License Application filing for lasme-cel in 2028, positioning upcoming readouts as key decision points for program value and partnering leverage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.